Bank of America backs Pharvaris on breakthrough for rare swelling disease
Bank of America upgraded Pharvaris (PHVS) to Buy with a $44 price target, citing strong trial results for its HAE treatment drug, deucrictibant. The stock closed at $31.41 on Oct. 23. BofA sees substantial upside and notes positive feedback from doctors. The FDA decisions in 2027 could impact the stock.
How this was made
The 30-second read
Why it matters
The Phase 3 trial data and BofA upgrade provide a clear catalyst that could push the stock higher, especially given the prior price pullback.
Market read
First report of pivotal trial data and analyst upgrade creates immediate trading interest in PHVS.
What to watch
Potential competition from BioCryst's oral therapy and the need for real‑world adoption data.
Background
Pharvaris (PHVS) is developing oral treatments for hereditary angioedema, a rare disease affecting ~7,500 U.S. patients.
Ticker impact
Bank of America upgraded PHVS to Buy after Phase 3 trial showed 83% attack reduction, keeping a $44 price target.
upward pressure as investors price in the upgrade and strong efficacy data
The upgrade is a fresh catalyst; Phase 3 results are material for a biotech and often trigger price gains.
Market effects
May lift other rare‑disease biotech stocks as investors seek similar pipeline opportunities.
Positive for US biotech sector, modest effect on broader market.
Limited to biotech investors; no broad macro impact.
Counterpoint
If FDA delays or safety concerns emerge, the stock could face sharp downside despite the upgrade.
Key entities
- analystBank of America
Upgraded PHVS to Buy and maintained a $44 price target.
- companyPharvaris
Biotech firm reporting Phase 3 trial results for deucrictibant.
